iBio, Inc. (IBIO)

NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
0.281
-0.004 (-1.44%)
Aug 16, 2022 1:18 PM EDT - Market open
-1.44%
Market Cap 61.30M
Revenue (ttm) 2.81M
Net Income (ttm) -33.29M
Shares Out 218.17M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,158,569
Open 0.291
Previous Close 0.285
Day's Range 0.281 - 0.300
52-Week Range 0.220 - 1.340
Beta -4.28
Analysts Buy
Price Target 1.79 (+537.0%)
Earnings Date Sep 26, 2022

About IBIO

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the pr... [Read more...]

Industry Biotechnology
Employees 49
Stock Exchange NYSEAMERICAN
Ticker Symbol IBIO
Full Company Profile

Financial Performance

In 2021, iBio, Inc.'s revenue was $2.37 million, an increase of 44.75% compared to the previous year's $1.64 million. Losses were -$23.21 million, 41.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IBIO stock is "Buy." The 12-month stock price forecast is 1.79, which is an increase of 537.01% from the latest price.

Price Target
$1.79
(537.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufact...

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharmi...

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPhar...

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufactu...

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharm...

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease

iBio Inc received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program.

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharm...

iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022

- Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - - Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -

iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting

BRYAN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based  FastPhar...

iBio Announces Partial Adjournment of Annual Meeting to December 22

- Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -

ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio's Upcoming Annual Meeting

- iBio's Board Urges Shareholders to Vote Today to Support Company's Strategic Growth Plans -

IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears

IBIO stock may have missed out on the success of larger vaccine makers, but it's hoping the omicron variant will change that. The post IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron ...

In Light Of Omicron Variant, iBio Issues Update For IBIO-202 COVID-19 Program

iBio Inc (NYSE: IBIO) announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2. Last week, the World Health Organiz...

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

- Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks -

Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of ...

BRYAN, Texas, Nov. 17, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharm...

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics -

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufactu...

iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharm...

6 Penny Stocks to Part With Before They Crash and Burn

Investing in penny stocks is always fraught with risk. However, these companies have dubious business models making them even riskier.

Other symbols: IVRPBFSNDLSOLO

iBio Acquires FastPharming Manufacturing Facility®

- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights -

New Strong Sell Stocks for October 29th

IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

Other symbols: BSETDVAINSMPOST

iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9

BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharm...

New Strong Sell Stocks for October 20th

GEL, WWD, IBIO, SI, and ATEC have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2021.

Other symbols: ATECGELSIWWD

This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream

Pre-clinical successes lead to exclusive licensing agreements for iBio.

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors